|
ZFP82 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.75279807229845E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.35319977445647E-10 |
| Normal-vs-Stage2 |
4.9379000000016E-07 |
| Normal-vs-Stage3 |
2.09999795330873E-11 |
| Normal-vs-Stage4 |
6.91668944341473E-14 |
| Stage1-vs-Stage2 |
2.878600E-01 |
| Stage1-vs-Stage3 |
2.213400E-01 |
| Stage1-vs-Stage4 |
1.519630E-03 |
| Stage2-vs-Stage3 |
9.177900E-02 |
| Stage2-vs-Stage4 |
1.795640E-03 |
| Stage3-vs-Stage4 |
4.604100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.18629558901284E-11 |
| Normal-vs-AfricanAmerican |
1.40010000004853E-06 |
| Normal-vs-Asian |
4.63299999475808E-08 |
| Caucasian-vs-AfricanAmerican |
9.054200E-01 |
| Caucasian-vs-Asian |
1.150570E-01 |
| AfricanAmerican-vs-Asian |
2.568400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.15570006290022E-10 |
| Normal-vs-Female |
2.73799871663982E-11 |
| Male-vs-Female |
6.497400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.6269986186378E-11 |
| Normal-vs-Age(41-60Yrs) |
2.44109954472549E-10 |
| Normal-vs-Age(61-80Yrs) |
2.98200353299194E-11 |
| Normal-vs-Age(81-100Yrs) |
3.258700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.697400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.107200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.370400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.852000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.771600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.148400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.27300000005459E-06 |
| Classical-VS-Follicular |
9.904200E-01 |
| Classical-VS-Other |
8.418000E-01 |
| Classical-VS-Normal |
4.32630042901394E-10 |
| Tall-VS-Follicular |
1.617080E-04 |
| Tall-VS-Other |
2.472000E-01 |
| Tall-VS-Normal |
1.11022302462516E-14 |
| Follicular-VS-Other |
8.574000E-01 |
| Follicular-VS-Normal |
2.06530004209782E-09 |
| Other-VS-Normal |
5.317000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.33640054157081E-10 |
| Normal-vs-N1 |
3.88244991711417E-13 |
| N0-vs-N1 |
3.062100E-03 |
|
|
